Kinesin

Kinesin Related Products (75):

By Effects:	Inhibitors (69) Activator (1) Modulator (1) Control (1)

Cat. No.	Product Name	Effect	Purity

HY-132840

Sovilnesib	Inhibitor	99.90%
Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC₅₀ value of 0.071 μM. Sovilnesib can be used for the research of cancer.

HY-153065

KIF18A-IN-6	Inhibitor	98.48%
KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC₅₀ of 0.016 μM against KIF18A microtubule-dependent ATPase activity.

HY-153066

VLS-1272	Inhibitor	99.63%
VLS-1272 (Compound 22) is an orally active KIF18A inhibitor that binds to the KIF18A-microtubule complex in an ATP-noncompetitive manner (IC₅₀ = 41 nM), blocking its ATPase activity and inhibiting microtubule translocation. This leads to abnormal accumulation of KIF18A at spindle poles, disrupting chromosome alignment and inducing mitotic arrest and apoptosis in CIN^High tumor cells (e.g., ovarian cancer OVCAR-3, breast cancer JIMT-1). VLS-1272 is a promising candidate for anti-tumor research.

HY-101770

BTB-1	Inhibitor	99.91%
BTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC₅₀ of 1.69 μM.

HY-112777

Kinesore	Modulator	98.0%
Kinesore is an inhibitor of the KLC2-SKIP Interaction.

HY-177613B

ALN-12115 sodium scrambled negative control	Inhibitor
ALN-12115 sodium scrambled negative control is the sequence scrambled negative control of ALN-12115 sodium.

HY-180641

KIF18A-IN-19	Inhibitor
KIF18A-IN-19 (Compound 1) is an orally active KIF18A inhibitor with an IC₅₀ of <0.1 μM. KIF18A-IN-19 has anti-cancer activity against ovarian cancer.

HY-177876

Cenpemlin	Inhibitor
Cenpemlin is a CENP-M inhibitor that disrupts the CENP-M/CENP-L interaction. Cenpemlin can be used for investigating centromere-kinetochore interactions and dynamic kinetochore assembly during cell division.

HY-145034

KIF18A-IN-1	Inhibitor	98.06%
KIF18A-IN-1 is an inhibitor of the mitotic kinesin KIF18A with anti-tumor activity. KIF18A targeted inhibitors may activate mitotic checkpoints and selectively kill chromosomally unstable cancer cells.

HY-173522

KIF2C-IN-1	Inhibitor	98.08%
KIF2C-IN-1 is a cell-penetrating, selective KIF2C inhibitor with fluorescent properties (E_x/E_m = 410/510 nm). KIF2C-IN-1 exhibits notable cytotoxicity and weak inhibitory effects on KIF2A/B. KIF2C-IN-1 prohibits the dissociation of KIF2C from microtubules. KIF2C-IN-1 inhibiting KIF2C reverses cross-resistance to microtubule-targeting agents. KIF2C-IN-1 reduces tumorigenesis in chemoresistant triple-negative breast cancer (TNBC) model in mice with the combination of Paclitaxel (HY-B0015).

HY-162110

AM-9022	Inhibitor	99.53%
AM-9022 is an orally active, potent, selective KIF18A inhibitor that can be used for research on cancer.

HY-160441

MC-Val-Cit-PAB-Ispinesib	Inhibitor	99.85%
MC-Val-Cit-PAB-Ispinesib (Compound 509) is a drug-linker conjugate for ADC, consisting of a cleavable ADC linker and Eg5 inhibitor. MC-Val-Cit-PAB-Ispinesib can be used for the synthesis of antibody-drug conjugates (ADCs).

HY-13224

AZD4877	Inhibitor	99.49%
AZD4877 is another isostere to Ispinesib (HY-50759)and also a kinesin spindle protein (Eg5) inhibitor with IC₅₀ of 2 nM.AZD4877 arrests cell mitosis, leads to the formation of the monopolar spindle phenotype and induces apoptosis. AZD4877 inhibits circulating peripheral blood mononuclear cells (PBMCs) and has anti-cancer activity.

HY-115570

GW406108X	Inhibitor	98.0%
GW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC₅₀ of 0.82 uM in ATPase assays. GW406108X, a potent autophagy inhibitor, shows ATP competitive inhibition against ULK1 with a pIC₅₀ of 6.37 (427 nM). GW406108X inhibits ULK1 kinase activity and blocks autophagic flux, without affecting the upstream signaling kinases mTORC1 and AMPK.

HY-144894

AM-5308	Inhibitor	99.15%
AM-5308 is the inhibitor for KIF18A (IC₅₀=47 nM) that inhibits KIF18A-mediated microtubule ATPase activity. AM-5308 activates mitotic checkpoints, regulates cell division processes, including chromosome segregation and spindle assembly. AM-5308 exhibits antitumor activity.

HY-118961

SR31527 chloride	Inhibitor
SR31527 chloride is a potent KIFC1 inhibitor with an IC₅₀ value of 6.6 µM. SR31527 chloride decreases cell viability and colony formation.

HY-15187A

(R)-Filanesib	Inhibitor	98.53%
(R)-Filanesib ((R)-ARRY-520) is the R-enantiomer of Filanesib (HY-15187). Filanesib is a synthetic kinesin spindle protein (KSP) inhibitor with an IC₅₀ of 6 nM.

HY-162937

KIF18A-IN-13	Inhibitor	99.93%
KIF18A-IN-13 (Compound 16) is an effective and orally active inhibitor of KIF18A with anticancer activity in vivo. KIF18A-IN-13 can be utilized for research in ovarian cancer.

HY-177246A

Mitotic kinesin-IN-1 hydrochloride	Inhibitor
Mitotic kinesin-IN-1 (Example 80) hydrochloride is a Mitotic kinesin inhibitor. Mitotic kinesin-IN-1 hydrochloride inhibits cell proliferation by suppressing mitosis. Mitotic kinesin-IN-1 hydrochloride can be used for cancer, cardiac hypertrophy, immune and inflammatory disorders, fungal infections research.

HY-110208

BRD9876		99.37%
BRD9876 is the “rigor” inhibitor that locks kinesin-5 (Eg5) in a state with enhanced microtubules (MTs) binding, leading to bundling and stabilization of MTs. BRD9876 interacts with the tyrosine 104 residue that is part of the α4-α6 allosteric binding pocket. BRD9876 specifically targets microtubule-bound Eg5 and selectively inhibits myeloma over CD34 cells. BRD9876 has the potential for multiple myeloma (MM) research.

Name
Email *

	Sorry, but the email address you supplied was invalid.